Clovis Oncology Equity 2024

Clovis Oncology Aktienanalyse

What does Clovis Oncology do?

Clovis Oncology Inc. is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. The company is based in Boulder, Colorado and was founded in 2009. They focus on researching and developing innovative therapies for cancer patients. History: Clovis Oncology was founded by Patrick Mahaffy and his team, who previously worked at Pharmion Corporation and sold the biotech company to Celgene. After the sale of Pharmion, Mahaffy and his colleagues wanted to build something new and started Clovis Oncology. Clovis started its activities in 2009 and initially focused on the development of PARP inhibitors, which can be used for the treatment of breast and ovarian cancer. In 2011, the company conducted Phase I studies with its leading product candidate, Rucaparib. Business model: Clovis Oncology has a business model based on the discovery, development, and commercialization of innovative cancer therapies. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a global network of research and development facilities that allows them to focus on the therapy areas where they are best positioned. Through partnerships and licenses, the company also has access to specialized technologies and expertise in cancer research. Divisions: Clovis Oncology is divided into two divisions: 1. Research and development: Clovis operates an intensive research and development program focused on the discovery and development of new cancer therapies. The focus is on developing PARP inhibitors that offer new treatments for breast and ovarian cancer. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a strong pipeline of products in various stages of clinical development. 2. Commercialization: Clovis also has an experienced marketing team responsible for the marketing and distribution of Rucaparib. Rucaparib is a PARP inhibitor approved for the treatment of breast and ovarian cancer in the United States and several other countries. Products: The main product of Clovis Oncology is Rucaparib, a PARP inhibitor for the treatment of breast and ovarian cancer. The medication was approved by the US Food and Drug Administration (FDA) in December 2016 for use in patients with advanced ovarian cancer. Clovis also has a pipeline of products in various stages of clinical development. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Summary: Clovis Oncology is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. They have a focus on developing PARP inhibitors and currently offer Rucaparib for the treatment of breast and ovarian cancer. Clovis has a strong pipeline of products in various stages of clinical development and collaborates closely with academic institutions and other companies to advance cancer research. Clovis Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Clovis Oncology's Equity

Clovis Oncology's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Clovis Oncology's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Clovis Oncology's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Clovis Oncology's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Clovis Oncology’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Clovis Oncology Stock

What is the equity of Clovis Oncology this year?

Clovis Oncology has equity of -278.84 M USD this year.

What was the equity of Clovis Oncology compared to the previous year?

The equity of Clovis Oncology has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Clovis Oncology?

A high equity is advantageous for investors of Clovis Oncology as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Clovis Oncology?

A low equity can be a risk for investors of Clovis Oncology, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Clovis Oncology affect the company?

An increase in equity of Clovis Oncology can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Clovis Oncology affect the company?

A reduction in equity of Clovis Oncology can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Clovis Oncology?

Some factors that can affect the equity of Clovis Oncology include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Clovis Oncology so important for investors?

The equity of Clovis Oncology is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Clovis Oncology take to change the equity?

To change equity, Clovis Oncology can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Clovis Oncology pay?

Over the past 12 months, Clovis Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Clovis Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Clovis Oncology?

The current dividend yield of Clovis Oncology is .

When does Clovis Oncology pay dividends?

Clovis Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Clovis Oncology?

Clovis Oncology paid dividends every year for the past 0 years.

What is the dividend of Clovis Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Clovis Oncology located?

Clovis Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clovis Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clovis Oncology from 6/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Clovis Oncology pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of Clovis Oncology in the year 2023?

In the year 2023, Clovis Oncology distributed 0 USD as dividends.

In which currency does Clovis Oncology pay out the dividend?

The dividends of Clovis Oncology are distributed in USD.